Mumbai-Based USV & Biogenomics Launch INSUQUICK, India's First Biosimilar Insulin Aspart

This 'Make in India' product, developed entirely using indigenous technology, has undergone rigorous clinical testing to meet global quality standards and is now available in all metros and Tier I/II cities.

In a significant development for diabetes care, Mumbai-based USV and Thane-based Biogenomics jointly introduced INSUQUICK, India's first biosimilar Insulin Aspart. 

This 'Make in India' product, developed entirely using indigenous technology, has undergone rigorous clinical testing to meet global quality standards and is now available in all metros and Tier I/II cities.

Prashant Tewari, managing director of USV, highlighted the strategic move into injectables. He said, "Our collaboration with Biogenomics is aimed at providing high-quality insulin aspart for individuals dealing with diabetes."

The insulin product, available in cartridges, vials, and prefilled disposable pens, offers flexibility tailored to the diverse needs of diabetes patients. These contemporary pens feature a lightweight design, legible scale, and audible clicks for precise settings.

InsuQuick's availability provides more treatment options for the growing number of people diagnosed with diabetes in India. With over 101 million adults living with diabetes and an additional 136 million at risk of developing the condition, the biosimilar addresses a critical healthcare need.

Dr Archana Krishnan, cofounder and director of Biogenomics, highlighted the indigenous technology used in creating the biosimilar, ensuring structural similarity and a robust clinical program to establish efficacy and safety.

The product's pricing strategy, with a cartridge at INR 700, VDPen at INR 915, and vial at INR 2321, aims to make the biosimilar accessible to a wide range of consumers in metros and Tier I/II cities.

Insulin Aspart serves as USV's entry into the insulin market, with plans for further expansion in the coming years. The company is committed to ongoing research and development to provide comprehensive solutions for diabetes management.

In another notable healthcare initiative on World Diabetes Day, Fortis-CDOC has inaugurated a diabetes remission clinic in collaboration with Twin Health USA, incorporating innovative Whole-Body Digital Twin™ technology.

The clinic aims to provide comprehensive diabetes care through personalised strategies focusing on nutrition, sleep, and physical activity. The Whole-Body Digital Twin™ technology, utilising advanced algorithms and machine learning, tailors advice for lifestyle modifications, contributing to effective disease management.

Further contributing to diabetes care, AIIMS Delhi launched a free insulin distribution service for economically disadvantaged patients. This initiative, operating in outpatient departments and consultation services, provides free insulin vials to prescribed patients.